Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Merck & Co, Inc.
Community Practice Connections™: Melanoma Tumor Board: Matching Treatment to Patient
Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based
The management of melanoma has shifted in recent years, with improved understanding of signaling pathways and resistance mechanisms underlying the pathogenesis of metastatic melanoma. This has led to advances in the development of targeted therapies. These new approaches have given physicians the ability to target previously unreachable treatment goals to improve patient outcomes. Novel treatment strategies for advanced melanoma raise challenging questions, and uncertainty often arises regarding the best strategies for integrating new treatments into current treatment paradigms, in addition to concerns for the proactive management of treatment-related adverse events. The ability to evaluate efficacy of new therapies, manage adverse events, and implement biomarkers for selecting therapy is critical for making informed decisions and optimizing patient care. This educational activity is based on a live symposium held adjunct to the 2019 clinical oncology annual meeting in Chicago. Through a series of written passages and brief video interviews, expert faculty review the impact of clinical data on patient care, discuss clinical cases, and share forward-looking perspectives on the treatment of advanced melanoma.
Benefits of Participating
- Hear expert perspectives and recommendations for treating stage III melanoma
- Learn about the latest in biomarker development
- Become more aware of managing adverse events s of immunotherapy
- Get insights on sequencing strategies for advanced melanoma
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Merck & Co, Inc.
Instructions for This Activity and Receiving Credit
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with melanoma. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of melanoma may also participate.
Upon successful completion of this educational activity, you should be better prepared to:
- Assess recently reported clinical trial data for safety and efficacy of emerging therapies, novel combinations, and therapeutic sequencing strategies for melanoma treatment
- Apply best practices to proactively identify and mitigate the impact of treatment-related toxicities in settings where patients with melanoma are managed
- Discuss emerging data on the use of biomarkers to guide individualized care for patients with melanoma
- Integrate emerging data on therapeutic sequencing options into the context of treatment for patients with melanoma
Faculty, Staff, and Planners’ Disclosures
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY
Disclosures: Grant/Research Support: Bristol-Myers Squibb, Merck, GlaxoSmithKline, Genentech, Astellas Pharma, Incyte, Roche, Novartis, NextCure; Consultant: Celldex, Ichor Medical Systems, BioND, Altor BioSciences, Bristol-Myers Squibb, Merck, Genentch, Roche, Amgen, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, AbbVie, Eisai, CytomX Therapeutics, Nektar, Novartis, Sellas, WindMIL, Takeda; Shareholder: Altor BioScience, BioND, CytomX Therapeutics, Protean BioDiagnostics; Honoraria: Bristol-Meyers Squibb, Merck, Genentch, AbbVie, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eisai, Altor BioScience, Amgen, Roche, Ichor Medical Systems, Celldex, CytomX Therapeutics, Nektar, Novartis, Sellas, WindMIL, Takeda, Protean BioDiagnostics; Travel/Accomodations: Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Roche, Celldex, Amgen, Merck, AstraZeneca, Genetech, Novartis, WindMIL, Takeda.
Chief of Research/Immuno-Oncology
Co-Director, Cutaneous Malignancy Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosures: Grant Research Support: Amgen, Arcus, Astellas, AstraZen¬eca, Bristol-Myers Squibb, Celldex, CytomX Therapeutics, Genentech, GlaxoSmithKline, Immunocore, Incyte, Iovance, Merck, Merck Serono, MedImmune, NextCure, Novartis, Parker Institute, Pfizer, Polynoma, Regeneron, Roche.
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Disclosures: Grant Research Support: Merck, Bristol-Myers Squibb; Consultant: Bristol-Myers Squibb, Novartis, Array.
Professor of Medicine (Medical Oncology)
Yale School of Medicine
Co-Director of Yale SPORE in Skin Cancer
Yale Cancer Center
New Haven, CT
Disclosures: Consultant: Genetech/Roche, Bristol-Myers Squibb, AstraZeneca/Medimmune, Novartis, Seattle Genetics, Nektar, Lilly, Biodesix, Modulate Therapeutics, NewLink Genetics, Molecular Partners, Innate Pharma, AbbVie, Immunocore, Genmab, Almac, Hinge, Allakos, Anaeropharma, Array; Scientific Advisory Board: Symphogen, Adaptimmune, Omniox, Lycera (no longer active), Pieris; Torque (consulting fees and stock options), Verseau.
The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.